Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim reports positive lung cancer trial data

Boehringer Ingelheim reports positive lung cancer trial data

6th June 2013

Boehringer Ingelheim has reported positive data from a new study of nintedanib, showing its ability to extend the life of lung cancer patients with adenocarcinoma.

Results from the phase III LUME-Lung 1 study revealed that the oral triple angiokinase inhibitor extended survival by 2.3 months for non-small cell lung cancer (NSCLC) adenocarcinoma patients when added to docetaxel chemotherapy, compared to placebo plus docetaxel.

This is the first time a second-line treatment has demonstrated overall survival benefits for NSCLC sufferers in nearly ten years, suggesting nintedanib could be the first anti-angiogenic treatment to benefit these patients after initial chemotherapy has failed.

Professor Klaus Dugi, corporate senior vice-president medicine at Boehringer Ingelheim, said: "At Boehringer Ingelheim, we recognise that lung cancer is not just one disease and we want to ensure the best outcome for patients."

This comes after the firm also released phase III data showing the efficacy of afatinib in the treatment of EGFR mutation-positive advanced lung cancer earlier this week.ADNFCR-8000103-ID-801595379-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.